Cellectis, Sanofi partner on UCART clinical trials

By The Science Advisory Board staff writers

May 12, 2021 -- Sanofi has agreed to supply anti-CD52 monoclonal antibody alemtuzumab for use in a lymphodepleting regimen in Cellectis-sponsored universal chimeric antigen receptor T-cell (UCART) trials.

Using alemtuzumab in a lymphodepleting regimen should reduce a patient's host immune cells and improve allogeneic CAR T-cell expansion and persistence. UCART T cells are being evaluated for the treatment of relapsed/refractory acute lymphocytic leukemia and relapsed/refractory acute myeloid leukemia.

The companies agreed to execute a commercial supply of alemtuzumab, although financial details were not disclosed.

Sanofi, Stanford partner to study immunology
Sanofi has entered into a three-year research collaboration with the Stanford University School of Medicine to advance the understanding of immunology...
Sanofi to provide fill/finish services for Moderna COVID-19 vaccine
Moderna has inked a new agreement with Sanofi in order to scale up U.S. manufacturing capacity for its COVID-19 vaccine.
Sanofi acquires Tidal Therapeutics, expands vaccine manufacturing
Sanofi announced that it has purchased Tidal Therapeutics for $160 million and plans to expand its vaccine manufacturing capability through a site...
Sanofi to build new manufacturing facility in Toronto
Sanofi announced an investment of approximately $737 million U.S. in a new vaccine manufacturing facility at its existing site in Toronto, Canada,...
Cytovia, Cellectis partner on gene-edited NK cells
Cytovia Therapeutics and Cellectis have entered into a strategic research and development collaboration to develop gene-edited natural killer (NK) and...

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter